Table 1.

Change in eGFR at week 104 from baseline, based on serum creatinine or cystatin C

	SGLT2i N = 550		No SGLT2i N = 2,983
Based on serum creatinine (ml min−1/1.73 m2)
Semaglutide	−1.6 (0.77) (−3.1, −0.0) n = 268		−4.1 (0.34) (−4.8, −3.4) n = 1,381
Placebo	−5.3 (0.78) (−6.8, −3.7) n = 260		−7.3 (0.35) (−8.0, −6.6) n = 1,364
Between-group difference semaglutide – placebo	3.7 (1.09) (1.6, 5.8)		3.2 (0.49) (2.3, 4.2)
P value	<0.001		<0.001
P interaction value		0.686
Based on cystatin C (ml min−1/1.73 m2)
Semaglutide	−0.2 (0.67) (−1.6, 1.1) n = 263		−2.4 (0.30) (−2.9, −1.8) n = 1,357
Placebo	−3.8 (0.67) (−5.1, −2.4) n = 254		−5.7 (0.30) (−6.3, −5.1) n = 1,333
Between-group difference semaglutide – placebo	3.5 (0.95) (1.6, 5.4)		3.4 (0.43) (2.5, 4.2)
P value	<0.001		<0.001
P interaction value		0.901

Data shown are mean estimates (s.e.) (95% CI) from the in-trial period. P interaction values for differences between semaglutide and placebo are shown for the analyses based upon serum creatinine and cystatin C. Responses were analyzed using an ANCOVA with treatment by SGLT2i group as fixed factor and baseline value as covariate. Before analysis, missing data were multiple imputed. The imputation model (linear regression) was done separately for each treatment arm, included baseline value as a covariate, and was fitted to all participants with a measurement regardless of treatment status at week 104. Mean estimates were adjusted according to observed baseline distribution. Two-sided P value for test of no treatment difference using a t-test within SGLT2i group and an F-test for interaction effect between treatment by SGLT2i group. ANCOVA, analysis of covariance; s.e., standard error.